Bayer Shares Approach Critical €30 Threshold

Bayer’s stock faces a pivotal moment as Germany’s DAX-listed pharmaceutical and agricultural giant tests the psychologically significant €30 price level. Following years of pressure from glyphosate litigation and structural challenges, the company may be positioned for a substantial turnaround. The critical question for investors is whether the current momentum can be sustained through upcoming catalysts.

Organizational Restructuring Gains Traction

Under CEO Bill Anderson’s leadership, Bayer is implementing a radical transformation strategy dubbed “Dynamic Shared Ownership.” The ambitious program aims to dismantle corporate hierarchies, slash bureaucratic processes, and accelerate decision-making by the end of 2025. Significant workforce reductions are expected to generate substantial cost savings at a crucial juncture for the company’s financial health.

Pharmaceutical Pipeline Shows Promise

Investor enthusiasm is being fueled primarily by developments within Bayer’s pharmaceutical division, where multiple promising drug candidates are generating optimism. The most significant near-term opportunity appears to be Elinzanetant, a treatment for menopausal symptoms that has already secured regulatory approval in both the United Kingdom and Canada. The recent recommendation for European Union authorization marks a critical milestone for accessing the continent’s multi-billion euro market.

Additional pharmaceutical developments strengthening the investment case include:
* Submission of a marketing application in China for lung cancer treatment Sevabertinib
* Ongoing accelerated review procedures in the United States
* Enhancement of the oncology pipeline through licensing of a PRMT5 inhibitor

Should investors sell immediately? Or is it worth buying Bayer AG?

Glyphosate Litigation Landscape Shifts

The long-standing legal cloud hanging over Bayer may be showing signs of dissipation. In a potentially positive development for the company, the U.S. Supreme Court has requested the government’s position in the “Durnell” case. A favorable ruling from the nation’s highest court by 2026 could substantially reduce the flood of lawsuits and eliminate the largest uncertainty currently depressing the stock’s valuation.

Technical Analysis Points to Critical Juncture

From a chart perspective, Bayer shares present a compelling technical setup. Having surged more than 50% since the beginning of the year, the equity now tests its 52-week high. The €30 level represents a significant technical barrier—a decisive and sustained breakthrough above this resistance could unlock further upside potential.

The coming weeks will prove decisive for Bayer’s recovery narrative. Third-quarter results scheduled for November must validate the current optimistic sentiment. Should the company deliver both operational progress and a technical breakout above €30, a comprehensive re-rating of the long-depressed shares could commence. All eyes remain fixed on whether Bayer can maintain its current trajectory.